Trials / Terminated
TerminatedNCT02612701
E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Cedars-Sinai Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions remain about the size and composition and especially about the potential toxicity of these particles. Thus, a key unanswered question-and the research question proposed-is whether e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as does conventional cigarette smoke, which delivers a very well-defined exposure to fine particles and many fold greater exposure to toxic (combustion) products including volatile organic compounds (such as acrolein) that have been implicated in the pathogenesis of tobacco-related coronary disease. Because the effects of nicotine on the human coronary microcirculation remain incompletely defined-with multiple potential vasodilator and vasoconstrictor actions each of which may vary by dose-we will determine the comparative effects of conventional cigarette smoke against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose nicotine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Cigarettes | Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg) |
| OTHER | E-cigarettes (nicotine free e-liquid) | Subjects will smoke nicotine free e-liquid with an e-cigarette. |
| OTHER | E-cigarettes (low nicotine e-liquid) | Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette. |
| OTHER | E-cigarettes (high nicotine e-liquid) | Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette. |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-10-01
- Completion
- 2020-10-01
- First posted
- 2015-11-24
- Last updated
- 2021-02-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02612701. Inclusion in this directory is not an endorsement.